Aviragen Therapeutics to Participate in FBR & Co. Healthcare Series Focused on Infectious Diseases
April 14 2016 - 4:01PM
Aviragen Therapeutics, Inc., (NASDAQ:AVIR), formerly Biota
Pharmaceuticals, Inc., today announced that Joseph Patti, PhD,
President & CEO of Aviragen Therapeutics, will participate in a
panel discussion titled, “Notable Emerging Anti-Viral Agents” as
part of the FBR & Co. New Prescriptions: Innovation in the
Treatment of Diseases and Infections conference.
The panel discussion will take place at 10:30am
ET on Wednesday, April 20, 2016 at the JW Marriott Essex House in
New York.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the
discovery and development of the next generation of direct-acting
antivirals to treat infections that have limited therapeutic
options and affect a significant number of patients globally. The
Company has three product candidates in active clinical
development: These include vapendavir, an oral treatment for human
rhinovirus upper (HRV) respiratory infections in moderate-to-severe
asthmatics currently being evaluated in the Phase 2b SPIRITUS
trial; BTA585, an oral fusion protein inhibitor that has received
Fast Track designation by the U.S. FDA, in Phase 2 development for
the treatment and prevention of respiratory syncytial virus (RSV)
infections; and BTA074, a topical antiviral treatment in Phase 2
development for condyloma caused by human papillomavirus types 6
& 11. For additional information about the Company, please
visit www.aviragentherapeutics.com.
Contacts:
Mark Colonnese
Executive Vice President and Chief Financial Officer
Aviragen Therapeutics, Inc.
(678) 221-3381
mcolonnese@aviragentherapeutics.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Sep 2023 to Sep 2024